Salarius Pharmaceuticals Inc [NASDAQ: SLRX] price plunged by -9.78 percent to reach at -$0.09.
The one-year SLRX stock forecast points to a potential upside of 96.69.
Guru’s Opinion on Salarius Pharmaceuticals Inc [SLRX]:
Ladenburg Thalmann have made an estimate for Salarius Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 27, 2020.
The Average True Range (ATR) for Salarius Pharmaceuticals Inc is set at 0.13 The Price to Book ratio for the last quarter was 0.82, with the Price to Cash per share for the same quarter was set at 1.39.
SLRX Stock Performance Analysis:
Salarius Pharmaceuticals Inc [SLRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.51. With this latest performance, SLRX shares dropped by -23.47% in over the last four-week period, additionally sinking by -47.74% over the last 6 months – not to mention a drop of -82.72% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLRX stock in for the last two-week period is set at 32.85, with the RSI for the last a single of trading hit 30.85, and the three-weeks RSI is set at 36.02 for Salarius Pharmaceuticals Inc [SLRX]. The present Moving Average for the last 50 days of trading for this stock 1.6136, while it was recorded at 0.9234 for the last single week of trading, and 1.8197 for the last 200 days.
Insight into Salarius Pharmaceuticals Inc Fundamentals:
Salarius Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.83 and a Current Ratio set at 1.83.
Salarius Pharmaceuticals Inc [SLRX] Institutonal Ownership Details
There are presently around $4.80%, or 4.90%% of SLRX stock, in the hands of institutional investors.
